Puma Biotechnology Stock Buy Hold or Sell Recommendation
| PBYI Stock | USD 5.35 0.08 1.52% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Puma Biotechnology is 'Strong Sell'. Macroaxis provides Puma Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PBYI positions. The advice algorithm takes into account all of Puma Biotechnology's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Puma Biotechnology's buy or sell advice are summarized below:
Real Value 4.85 | Target Price 5 | Hype Value 5.29 | Market Value 5.35 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Puma Biotechnology given historical horizon and risk tolerance towards Puma Biotechnology. When Macroaxis issues a 'buy' or 'sell' recommendation for Puma Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
Puma |
Execute Puma Biotechnology Buy or Sell Advice
The Puma recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Puma Biotechnology. Macroaxis does not own or have any residual interests in Puma Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Puma Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Puma Biotechnology Trading Alerts and Improvement Suggestions
| Puma Biotechnology had very high historical volatility over the last 90 days | |
| Puma Biotechnology has a strong financial position based on the latest SEC filings | |
| About 67.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Puma Biotech Stock Dips While Market Gains Key Facts |
Puma Biotechnology Returns Distribution Density
The distribution of Puma Biotechnology's historical returns is an attempt to chart the uncertainty of Puma Biotechnology's future price movements. The chart of the probability distribution of Puma Biotechnology daily returns describes the distribution of returns around its average expected value. We use Puma Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Puma Biotechnology returns is essential to provide solid investment advice for Puma Biotechnology.
| Mean Return | 0.33 | Value At Risk | -8.01 | Potential Upside | 10.03 | Standard Deviation | 5.69 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Puma Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Puma Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Puma Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Puma Biotechnology backward and forwards among themselves. Puma Biotechnology's institutional investor refers to the entity that pools money to purchase Puma Biotechnology's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2023-12-31 | 444 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 376.3 K | Marshall Wace Asset Management Ltd | 2023-12-31 | 348.6 K | Rice Hall James & Associates, Llc | 2023-12-31 | 329.9 K | Sei Investments Co | 2023-12-31 | 291.9 K | Two Sigma Advisers, Llc | 2023-12-31 | 284.8 K | Gsa Capital Partners Llp | 2023-12-31 | 262.3 K | Goldman Sachs Group Inc | 2023-12-31 | 231.9 K | Two Sigma Investments Llc | 2023-12-31 | 215.2 K | Vanguard Group Inc | 2023-12-31 | 3.8 M | Millennium Management Llc | 2023-12-31 | 3.2 M |
Puma Biotechnology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (39.5M) | 24.2M | (22.2M) | 3.5M | 8.4M | 8.8M | |
| Free Cash Flow | 22.1M | (19.2M) | 20.7M | (22.8M) | 14.4M | 15.1M | |
| Other Non Cash Items | 9.3M | 1.0M | 7.2M | 7.0M | 45.3M | 47.5M | |
| Capital Expenditures | 306K | 20.0M | 1K | 7M | 12.6M | 6.7M | |
| Net Income | (75.6M) | (60.0M) | (29.1M) | 2K | 21.6M | 22.7M | |
| End Period Cash Flow | 73.2M | 97.5M | 75.3M | 78.8M | 84.6M | 71.4M | |
| Change To Inventory | (545K) | (284K) | (3.7M) | 2.6M | (2.6M) | (2.4M) | |
| Net Borrowings | 48.4M | 100.8M | (68.4M) | (1.5M) | (1.4M) | (1.3M) | |
| Depreciation | 8.1M | 10.0M | 10.6M | 8.9M | 11.5M | 12.1M | |
| Change To Netincome | 66.6M | 37.6M | 39.8M | 18.8M | 21.7M | 20.6M | |
| Change Receivables | (8.1M) | 2.4M | (6.0M) | (7.8M) | (7.0M) | (6.7M) | |
| Investments | 5.5M | 43.4M | (10.9M) | 14.1M | (22.8M) | (21.7M) |
Puma Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Puma Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Puma Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Puma stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.23 | |
β | Beta against NYSE Composite | 1.59 | |
σ | Overall volatility | 5.45 | |
Ir | Information ratio | 0.05 |
Puma Biotechnology Volatility Alert
Puma Biotechnology exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Puma Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Puma Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Puma Biotechnology Fundamentals Vs Peers
Comparing Puma Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Puma Biotechnology's direct or indirect competition across all of the common fundamentals between Puma Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Puma Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Puma Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Puma Biotechnology to competition |
| Fundamentals | Puma Biotechnology | Peer Average |
| Return On Equity | 0.58 | -0.31 |
| Return On Asset | 0.0919 | -0.14 |
| Profit Margin | 0.09 % | (1.27) % |
| Operating Margin | 0.21 % | (5.51) % |
| Current Valuation | 273.46 M | 16.62 B |
| Shares Outstanding | 48.21 M | 571.82 M |
| Shares Owned By Insiders | 15.12 % | 10.09 % |
| Shares Owned By Institutions | 66.90 % | 39.21 % |
| Number Of Shares Shorted | 3.29 M | 4.71 M |
| Price To Earning | 18.52 X | 28.72 X |
| Price To Book | 4.75 X | 9.51 X |
| Price To Sales | 1.08 X | 11.42 X |
| Revenue | 235.64 M | 9.43 B |
| Gross Profit | 172.94 M | 27.38 B |
| EBITDA | 44.78 M | 3.9 B |
| Net Income | 21.59 M | 570.98 M |
| Cash And Equivalents | 77.96 M | 2.7 B |
| Cash Per Share | 1.71 X | 5.01 X |
| Total Debt | 111.49 M | 5.32 B |
| Debt To Equity | 5.19 % | 48.70 % |
| Current Ratio | 2.04 X | 2.16 X |
| Book Value Per Share | 1.12 X | 1.93 K |
| Cash Flow From Operations | 27.01 M | 971.22 M |
| Short Ratio | 4.41 X | 4.00 X |
| Earnings Per Share | 0.45 X | 3.12 X |
| Price To Earnings To Growth | 0.03 X | 4.89 X |
| Target Price | 4.33 | |
| Number Of Employees | 185 | 18.84 K |
| Beta | 1.31 | -0.15 |
| Market Capitalization | 257.91 M | 19.03 B |
| Total Asset | 230.53 M | 29.47 B |
| Retained Earnings | (1.35 B) | 9.33 B |
| Working Capital | 56.8 M | 1.48 B |
Note: Acquisition by Wong Alvin F of 58601 shares of Puma Biotechnology subject to Rule 16b-3 [view details]
Puma Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Puma . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Puma Biotechnology Buy or Sell Advice
When is the right time to buy or sell Puma Biotechnology? Buying financial instruments such as Puma Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Liabilities | 229.0M | 200.5M | 177.1M | 108.6M | Other Stockholder Equity | 1.4B | 1.4B | 1.4B | 762.9M |
Use Investing Ideas to Build Portfolios
In addition to having Puma Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hotels Thematic Idea Now
Hotels
Hotels, inns, motels, and other companies providing lodging and hospitality services. The Hotels theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hotels Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Puma Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Puma Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.78) | Earnings Share 0.45 | Revenue Per Share 4.999 | Quarterly Revenue Growth 0.099 | Return On Assets 0.0919 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.